Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

This story originally appeared on Zacks

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $42.51, moving +1.19% from the previous trading session. The stock lagged the S&P 500’s daily gain of 2.24%. Elsewhere, the Dow gained 2.51%, while the tech-heavy Nasdaq lost 0.2%.

– Zacks

Prior to today’s trading, shares of the company had gained 11.55% over the past month. This has outpaced the Medical sector’s loss of 1% and the S&P 500’s loss of 2.58% in that time.

Investors will be hoping for strength from Cassava Sciences, Inc. as it approaches its next earnings release. In that report, analysts expect Cassava Sciences, Inc. to post earnings of -$0.41 per share. This would mark a year-over-year decline of 355.56%.

Any recent changes to analyst estimates for Cassava Sciences, Inc. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Cassava Sciences, Inc. is currently sporting a Zacks Rank of #3 (Hold).

The Medical – Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 159, which puts it in the bottom 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cassava Sciences, Inc. (SAVA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.

https://www.entrepreneur.com/article/420729

Jinggo B Danuarta

Next Post

Biden, Putin signal bigger confrontation ahead over Ukraine

Sat Feb 26 , 2022
MOSCOW (AP) — The East-West faceoff over Ukraine escalated dramatically Tuesday, with Russian lawmakers authorizing President Vladimir Putin to use military force outside his country and U.S. President Joe Biden and European leaders responding by slapping sanctions on Russian oligarchs and banks. Both leaders signaled that an even bigger confrontation […]